No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.
HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.
Zhitong FinanceApr 26 19:40
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
TipRanksApr 26 18:15
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
PRNewswireApr 11 04:05
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
TipRanksApr 9 17:40
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
TipRanksApr 9 07:50
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects
TipRanksApr 8 23:35
No Data
No Data